Morgan Stanley analyst David Lebowitz upgraded Epizyme to Overweight from Equal Weight with a price target of $22, up from $12. The stock in after-hours trading is up 3%, or 40c, to $15.70. The analyst expects data this weekend at the American Society of Hematology meeting to bolster confidence in tazemetostat for follicular lymphoma. The data, which will include more mature results and median progression-free survival in the mutant patients, should be "incrementally positive," Lebowitz tells investors in a research note. The analyst raised his 2021 adjusted tazemetostat sales estimate to $23M from $18M and 2026 estimate to $733M from $377M.